Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The VENTI Trial: Inhaled Beta-2-agonists in Adult VSD Patients
NCT02914652Phase 4Completed
- Sponsor
- Aarhus University
- Start
- Oct 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of salbutamol in Ventricular Septal Defect (VSD) (3 arms), sponsored by Aarhus University. Primary endpoints: Minute Ventilation at Day 2, Peak Exercise Oxygen Uptake at Day 2 and 1 more. Started Oct 2016; status: completed.
02
Drugs
salbutamol
03
Conditions
Ventricular Septal Defect (VSD)
Beyond the preview
Go deeper on NCT02914652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914652.